Form 4: Veracyte Director Karin Eastham Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Karin Eastham exercised stock options and sold 10,000 shares of Veracyte (VCYT) common stock on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 1, 2024, Karin Eastham, a director of Veracyte, Inc. (VCYT), executed a transaction involving the company's common stock.
• Eastham exercised a stock option to purchase 10,000 shares at a price of $13.19 per share.
• Simultaneously, Eastham sold 10,000 shares of common stock at a weighted average price of $21.6528.
• The sales prices ranged from $21.45 to $22.09.
• These transactions were executed under a Rule 10b5-1 plan adopted on November 18, 2022.
• Following these transactions, Eastham directly owns 33,125 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 plan and doesn't necessarily indicate a change in the director's view of the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives and directors to utilize 10b5-1 plans to manage their stock transactions and avoid accusations of insider trading. The sale could be for personal financial planning reasons and doesn't necessarily reflect a negative outlook on the company.

Stakeholder Impact

• The transaction could have a minor impact on shareholders due to the sale of shares by a director, but the impact is likely limited given the pre-planned nature of the transaction.

Key Dates